Equities research analysts forecast that C.R. Bard, Inc. (NYSE:BCR) will report sales of $990.49 million for the current fiscal quarter, Zacks Investment Research reports. Eight analysts have provided estimates for C.R. Bard’s earnings, with estimates ranging from $987.00 million to $997.00 million. C.R. Bard reported sales of $941.90 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 5.2%. The company is expected to issue its next quarterly earnings report on Tuesday, October 24th.

According to Zacks, analysts expect that C.R. Bard will report full year sales of $990.49 million for the current fiscal year, with estimates ranging from $3.92 billion to $3.95 billion. For the next fiscal year, analysts expect that the firm will post sales of $4.15 billion per share, with estimates ranging from $4.09 billion to $4.23 billion. Zacks’ sales averages are a mean average based on a survey of research analysts that follow C.R. Bard.

C.R. Bard (NYSE:BCR) last released its quarterly earnings results on Thursday, July 27th. The medical instruments supplier reported $2.92 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.84 by $0.08. The business had revenue of $979.70 million during the quarter, compared to analyst estimates of $976.53 million. C.R. Bard had a net margin of 14.99% and a return on equity of 48.70%. The business’s revenue was up 5.2% on a year-over-year basis. During the same period last year, the business earned $2.54 EPS.

A number of equities analysts recently issued reports on BCR shares. Zacks Investment Research raised shares of C.R. Bard from a “hold” rating to a “buy” rating and set a $342.00 target price on the stock in a research report on Thursday, May 11th. BidaskClub raised shares of C.R. Bard from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 8th. Morgan Stanley lowered shares of C.R. Bard from an “overweight” rating to an “equal weight” rating in a research report on Monday, April 24th. BMO Capital Markets reaffirmed a “buy” rating and set a $255.00 target price on shares of C.R. Bard in a research report on Tuesday, April 11th. Finally, Jefferies Group LLC boosted their target price on shares of C.R. Bard from $237.00 to $317.00 and gave the stock a “hold” rating in a research report on Monday, April 24th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $285.67.

ILLEGAL ACTIVITY NOTICE: This report was first published by Daily Political and is owned by of Daily Political. If you are accessing this report on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The original version of this report can be read at https://www.dailypolitical.com/2017/08/07/c-r-bard-inc-nysebcr-expected-to-post-quarterly-sales-of-990-49-million.html.

Several large investors have recently modified their holdings of the stock. Cribstone Capital Management LLC purchased a new stake in shares of C.R. Bard during the first quarter valued at approximately $130,000. Contravisory Investment Management Inc. increased its position in shares of C.R. Bard by 349.2% in the first quarter. Contravisory Investment Management Inc. now owns 548 shares of the medical instruments supplier’s stock valued at $136,000 after buying an additional 426 shares during the period. Whittier Trust Co. increased its position in shares of C.R. Bard by 7.7% in the first quarter. Whittier Trust Co. now owns 591 shares of the medical instruments supplier’s stock valued at $147,000 after buying an additional 42 shares during the period. ClariVest Asset Management LLC bought a new position in shares of C.R. Bard during the first quarter valued at about $148,000. Finally, SRS Capital Advisors Inc. increased its position in shares of C.R. Bard by 0.7% in the first quarter. SRS Capital Advisors Inc. now owns 598 shares of the medical instruments supplier’s stock valued at $148,000 after buying an additional 4 shares during the period. Institutional investors own 85.32% of the company’s stock.

C.R. Bard (NYSE BCR) traded up 0.11% during midday trading on Friday, reaching $318.94. 720,732 shares of the company were exchanged. The firm has a market cap of $23.18 billion, a P/E ratio of 41.87 and a beta of 0.59. C.R. Bard has a one year low of $203.63 and a one year high of $323.27. The firm’s 50-day moving average is $317.93 and its 200-day moving average is $279.50.

The company also recently announced a quarterly dividend, which was paid on Friday, August 4th. Stockholders of record on Monday, July 24th were paid a $0.26 dividend. The ex-dividend date of this dividend was Thursday, July 20th. This represents a $1.04 annualized dividend and a dividend yield of 0.33%. C.R. Bard’s dividend payout ratio is presently 13.67%.

C.R. Bard Company Profile

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Get a free copy of the Zacks research report on C.R. Bard (BCR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for C.R. Bard (NYSE:BCR)

Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.